VENATORX PHARMACEUTICALS INC - TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.

On Jan 16, 2026, Department of Health and Human Services obligated $25,044,892.75 to VENATORX PHARMACEUTICALS INC for to advance a novel beta-lactamase inhibitor of penicillin binding proteins targeting mdr-acinetobacter baumannii.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 12 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in MALVERN, PA. The contract is scheduled through Jan 18, 2027 — approximately 9 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.